| HOME >> BIOLOGY >> TECHNOLOGY |
"We have chosen to swiftly implement the restructuring we deem necessary to effectively utilize cash assets while maintaining the resources to advance our priority clinical programs," added Cormack. "We continue to retain a highly qualified clinical and regulatory team with impressive experience bringing oncology drug candidates to the FDA and to market."
The combined company has a strong oncology pipeline addressing distinct
unmet needs in the treatment of cancer, including three candidates in
various stages of clinical development. The Company's lead candidate,
OGX-011, is being evaluated in five Phase 2 clinical trials, each of which
has completed patient enrollment. Interim study results have previously
been presented for each of the five clinical trials. Details on the
pipeline follow:
- OGX-011, also known as custirsen sodium, inhibits the production of
clusterin, a protein that is associated with treatment resistance in
a number of solid tumors, including prostate, breast, non-small cell
lung, ovarian, and bladder cancers. It has potential applicability as
a therapeutic in a broad number of cancers at different stages and
can potentially be used in combination with a variety of commonly
used cancer treatments, including chemotherapy, radiation therapy,
and hormone ablation therapy. Recently announced preliminary data in
a Phase 2 clinical trial evaluating OGX-011 in combination with
second-line chemotherapy in patients with hormone refractory prostate
cancer has shown that retreatment with docetaxel in combination with
'/>"/>| SOURCE OncoGenex Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |